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background: Hepatocyte growth factor (HGF) has shown promise in treating patients with critical limb ischemia (CLI). We performed this phase II 
study to assess the safety and efficacy of the intramuscular (IM) injection of VM202, plasmid DNA expressing 2 isoforms of HGF, in CLI patients.
methods: We enrolled 52 patients in Rutherford class 4-5. Patients were randomly assigned in a 2:2:1 fashion to low-dose VM202 (8 mg; n=21), 
high-dose VM202 (16 mg; n=20) or placebo (saline; n=11). IM injections were given in the affected index calf on days 0, 14, 28 and 42. Safety and 
efficacy of VM202 were evaluated over 12 months. Safety endpoints included monitoring adverse events (AE) according to severity and relationship 
to the study drug. Efficacy endpoints included a change in visual analog scale for pain, ulcer healing, ankle brachial index (ABI) and transcutaneous 
oxygen pressure (TcPO2).
results: A total of 438 AEs were reported in 49 of the 52 patients; all AEs were considered to be unrelated to the study treatment. Serious AEs 
were reported by 6 (54.5%), 9 (42.9%) and 11 (55%) placebo, low-dose and high-dose patients; the number of reported SAEs was 7, 26 and 19, 
respectively. One SAE (peroneal deep vein thrombosis) was probably related to the study drug. No malignancies or proliferative retinopathies were 
seen. One placebo and 1 low-dose patient died, but the deaths were deemed unrelated to the treatment. The high-dose group showed the most 
improvement in major efficacy parameters. TcPO2 significantly increased at 12 months in high-dose patients compared with low-dose and placebo 
groups (p50% 12 months after treatment in 88% (7/8) of high-dose and 77% (10/13) of low-dose patients compared with 20% (1/5) in the 
placebo group (p<0.05, placebo vs high or low-dose). Rest pain was reduced 9 months postinjection in 70% (14/20) of high-dose, 52% (11/21) of 
low-dose and 36% (4/11) of placebo patients (p=NS). The mean change in ABI from baseline to 9 months was higher in the high-dose (0.095) than 
in the low-dose (0.052) or placebo (0.004) groups (p=NS).
conclusions: These results suggest that VM202 injections are safe and may result in improvements in efficacy variables in CLI patients.
